VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type ...(cent. Common measures of blood su...),Health

Common measures of blood sugar include the percent of glycosylated hemoglobin (HbA1c) present in the blood, which gives an assessment of glucose control over the life of a red blood cell (90-120 days), and fasting plasma glucose (FPG), which is a measure of blood sugar at a specific point in time. Diabetes is diagnosed when FPG exceeds 125 mg/dL on two occasions. A newer measure of glucose control is the GlycoMark(TM) test, a blood test which gives a measure of the post-meal glucose spikes over a one to two week period. Since both fasting and post-prandial glucose contribute to what is measured by HbA1c, the addition of GlycoMark provides additional valuable measures of glycemic control. According to the Centers for Disease Control (CDC) and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.

About Postprandial Glucose (PPG) and GlycoMark(TM)

In addition to measurements of hemoglobin A1c and fasting plasma glucose, postprandial glucose levels are used to assess glycemic control. Postprandial (post-meal) glucose refers to blood sugar levels after patients have eaten. As HbA1c levels are reduced to normal levels, assessment of postprandial glucose levels allows for a more precise measure of 24-hour glycemic control. Postprandial glucose is measured indirectly through levels of 1,5-anhydroglucitol (1,5-AG) found in the blood. 1,5-AG levels rise when blood glucose levels are better controlled. GlycoMark(TM) is an FDA approved blood test to measure postprandial glucose via 1,5-AG levels. Increases in 1,5-AG levels represent better glycemic control for patients with type 2 diabetes.

About Qnexa(TM)

Qnexa (Q-NEX-uh) is a proprietary, low dose, controlled release formulation of phentermine and topiramate tha
'/>"/>